GALAPAGOS N.V./ BE0003818359 /
2024-11-15 9:44:15 PM | Chg. -0.620 | Volume | Bid9:59:55 PM | Ask9:59:55 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
25.700EUR | -2.36% | 601 Turnover: 15,770.240 |
25.340Bid Size: 117 | 26.140Ask Size: 117 | 1.68 bill.EUR | - | 7.96 |
Newsfile Corp
10-25
Trundless Expands Focus on Ecuador as a Top 2024 Travel Spot for Nature and Culture
Newsfile Corp
09-06
Metropolitan Touring Achieves Sustainability Benchmark with Carbon-Neutral Commitment
GlobeNewswire
08-23
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...
GlobeNewswire
08-01
Galapagos reports half-year 2024 financial results and provides second quarter business update
GlobeNewswire
06-14
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...
GlobeNewswire
05-30
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...
GlobeNewswire
05-15
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...
GlobeNewswire
04-30
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and E...
GlobeNewswire
04-04
Galapagos showcases innovative approach in hematological cancer care with clinical and translational...
GlobeNewswire
03-28
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
GlobeNewswire
03-26
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
GlobeNewswire
02-22
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Cl...
GlobeNewswire
01-04
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...